BiotechTube

Crizanlizumab + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sickle Cell Disease

Conditions

Sickle Cell Disease

Trial Timeline

Oct 24, 2024 → Apr 19, 2030

NCT ID
NCT06439082

About Crizanlizumab + Placebo

Crizanlizumab + Placebo is a phase 3 stage product being developed by Novartis for Sickle Cell Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06439082. Target conditions include Sickle Cell Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06439082Phase 3Recruiting

Competing Products

20 competing products in Sickle Cell Disease

See all competitors
ProductCompanyStageHype Score
Prasugrel + PlaceboDaiichi SankyoPhase 3
77
PrasugrelDaiichi SankyoPhase 1
33
Prasugrel + PlaceboDaiichi SankyoPhase 2
52
PrasugrelDaiichi SankyoPhase 2
52
LexiscanAstellas PharmaPhase 1
33
Placebo + DalteparinEisaiPhase 2
52
tadalafil + placeboEli LillyPhase 2
52
Prasugrel (clinical formulation) + Prasugrel (Orally Disintegrating Tablet [ODT])Eli LillyPhase 1
33
Lidocaine Iv + PlaceboJohnson & JohnsonPhase 2
52
ICA-17043Johnson & JohnsonPhase 3
77
TicagrelorAstraZenecaPhase 1
33
Ticagrelor granule + Ticagrelor pediatric tablets + Ticagrelor pediatric tablets suspended in water + Ticagrelor immediate release (IR) tablets (Commercial tablet)AstraZenecaPhase 1
33
Ticagrelor + PlaceboAstraZenecaPhase 2
52
Ticagrelor + PlaceboAstraZenecaPhase 3
77
Brilinta + PlaceboAstraZenecaPhase 3
77
Ticagrelor Dose 1a + Dose 2a + Ticagrelor Dose 1b + Dose 2bAstraZenecaPhase 2
52
vorinostatMerckPhase 2
52
Crizanlizuamb + Standard of CareNovartisPhase 2
52
CrizanlizumabNovartisApproved
85
HydroxyureaNovartisPhase 3
77

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85